Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

PCSK9s: Discount Prompts NICE Turnaround on Sanofi's Praluent

Executive Summary

HTA body NICE has Okayed PCSK9 inhibitors Repatha and Praluent for adults with primary hypercholesterolaemia or mixed dyslipidaemia for use on the National Health Service IN England and Wales. However, restrictions on prescribing will likely limit sales.

Advertisement

Related Content

Discounts Sway NICE As Novartis Outlines Concerns Over New Cancer Drugs Fund
Amgen's Harper Says Repatha Is Priced Right
Amgen Earnings Beat Expectations; Company Pushing Payers On Repatha

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register